Azitra, Inc. (AZTR) Stock Analysis & Investment Frameworks
Azitra, Inc. (AZTR) stock analysis on Invetso. Review Azitra, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Azitra, Inc. Company Overview
- Exchange: New York Stock Exchange Arca
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Azitra, Inc. Key Financial Metrics
- Market Cap: $1.92M
- Revenue: $N/A
- ROE: -205.45%
- ROIC: -159.45%
- Dividend Yield: N/A
About Azitra, Inc.
Azitra, Inc. is a pre-clinical biopharmaceutical company focused on developing precise treatments for various dermatological conditions. They innovate by utilizing engineered proteins and live biotherapeutic products to address skin diseases. The company's pipeline features several key therapeutic candidates: ATR-12: A genetically modified strain of S. epidermidis intended to treat Netherton syndrome, a specific skin disorder. ATR-04: Another modified S. epidermidis strain, designed to alleviate the papulopustular rash commonly experienced by cancer patients undergoing epidermal growth factor receptor inhibitor therapy. ATR-01: An engineered recombinant human filaggrin protein developed for the treatment of ichthyosis vulgaris, another dermatological ailment. Founded in 2014, Azitra, Inc. operates from its headquarters in Branford, Connecticut.
Azitra, Inc. Investment Frameworks
Invetso analyzes Azitra, Inc. (AZTR) across the following frameworks:
- Azitra, Inc. 10Y Growth Potential
- Azitra, Inc. Scenario Analysis
- Azitra, Inc. Risks & Opportunities
- Azitra, Inc. Economic Moat
- Azitra, Inc. Business Model
- Azitra, Inc. Management
- Azitra, Inc. SWOT Analysis
- Azitra, Inc. Porter's 5 Forces
- Azitra, Inc. PESTLE Analysis
- Azitra, Inc. ESG Analysis
